A study reported the incidence of opportunistic infections during ibrutinib treatment for hematological malignancies and identified potential risk factors.
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
New data from a phase 2 randomized trial suggest that stereotactic ablative radiotherapy to sites of metastases may prolong overall and progression-free survival.
Follicular lymphoma manifesting with skin involvement only is considered to be a more aggressive disease than PCFCL.
Prices paid to hospitals for privately insured patients in 2017 averaged 241 percent of what Medicare would have paid.
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
Among postmenopausal women, former smokers have a reduced risk for bladder cancer within the first 10 years of cessation.
A preexisting CD8+ T-cell response may be predictive of benefit from checkpoint blockade in SCLC.
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Legalization of recreational cannabis is not associated with changes in health care utilization, as measured by length of stay or health care costs.
For patients with locally advanced non-small cell lung cancer (NSCLC), deep-learning networks integrating computed tomography (CT) scans at multiple time points can improve clinical outcome predictions.
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
A new study challenges the recommended use of cotesting for cervical cancer screening.